<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Clostridium Difficile • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Clostridium Difficile • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/clostridium difficile/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/clostridium difficile/" />

<link rel="stylesheet" href="/wiki/style.css" />

<style>
  @font-face {
    font-family: "Concourse";
    src: url("/wiki/assets/fonts/concourse_3_regular.woff2") format("woff2");
    font-style: normal;
  }
  @font-face {
    font-family: "Equity";
    src: url("/wiki/assets/fonts/equity_a_regular.woff2") format("woff2");
    font-style: normal;
  }
</style>

  </head>
  <body class="h-screen bg-ember scroll-smooth">
    <div
      class="fixed top-0 w-screen"
    >
    <div class="flex items-center justify-between max-w-4xl px-4 py-4 mx-auto md:px-10 bg-ember bg-opacity-90">
     <a href="/wiki/"> <svg xmlns="http://www.w3.org/2000/svg" class="w-8 h-8" viewBox="0 0 20 20" fill="currentColor">
  <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z" />
</svg></a>

      <nav class="flex space-x-2 font-semibold uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 font-semibold rounded hover:bg-zinc-800 hover:text-zinc-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>

    <div class="flex items-center justify-center flex-none max-w-4xl px-6 mx-auto mt-32 mb-32">
      <div  class="font-serif prose prose-lg prose-h1:text-xl prose-h2:text-lg md:prose-2xl md:prose-h1:text-4xl md:prose-h2:text-3xl prose-hr:border-zinc-900 hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200"><h1 id="clostridium-difficile" tabindex="-1">clostridium difficile</h1>
<ul>
<li>related: <a href="/wiki/notes/ID/">ID</a>, <a href="/wiki/notes/fulminant%20clostridium%20difficile/">fulminant clostridium difficile</a></li>
</ul>
<!-- C diff rx, abx restriction -->
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20220731150538.png" alt=""></p>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/image-20200206203514691.png" alt=""></p>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20220712080650.png" alt=""></p>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20220814161754.png" alt=""></p>
<ul>
<li>Possibly restrict use of clindamycin, fluoroquinolones &amp; cephalosporins</li>
<li>Consider using <strong>aminoglycosides or trimethoprim-sulfamethoxazole</strong> instead of fluoroquinolones</li>
</ul>
<p>Recurrence of CDI is common, affecting approximately 15%-30% of patients whose condition initially responds to antimicrobial therapy, and is typically due to germination of persistent spores from the initial infection and not from drug resistance.</p>
<p><strong>Fidaxomicin</strong>, in a standard (10-day) or an extended and pulsed regimen, is recommended for the management of an <strong>initial recurrence</strong> of CDI.  A <mark>prolonged course of oral vancomycin given in a pulsed and tapered regimen</mark> (eg, 4 times daily for 10-14 days, twice daily for 7 days, daily for 7 days, every 2-3 days for 2-8 weeks) is an acceptable alternative.  Adjunctive therapy with <mark>bezlotoxumab</mark>, a monoclonal antibody targeting <em>C difficile</em> toxin B, is considered for patients with an especially high recurrence risk (eg, age &gt;65, immunocompromised status, severe CDI on presentation).</p>
<p>Oral vancomycin followed by rifaximin is an alternate treatment for further recurrences but is not recommended for the first CDI recurrence.</p>

      </div>
    </div>
    
     <div class="fixed hidden ml-8 right-[5%] 2xl:block top-48 border-l-2 border-zinc-600 px-2"> 
        
      </div>


    <div class="max-w-4xl p-2 mx-auto font-sans font-semibold uppercase bg-emberdark">Backlinks</div>
    <div class="mx-auto font-serif prose prose-lg hover:prose-a:bg-zinc-800 hover:prose-a:text-zinc-200">
      
      <!-- <hr /> -->



<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/ID/" class="peer">ID</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="id" tabindex="-1">ID</h1>
<ul>
<li>related: <a href="/wiki/notes/Step%203/">Step 3</a>, <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<hr>
<h2 id="mksap" tabindex="-1">MKSAP</h2>
<ul>
<li><a href="/wiki/notes/Central%20Nervous%20System%20Infections/">Central Nervous System Infections</a></li>
<li><a href="/wiki/notes/Prion%20Diseases%20of%20the%20Central%20Nervous%20System/">Prion Diseases of the Central Nervous System</a></li>
<li><a href="/wiki/notes/Skin%20and%20Soft%20Tissue%20Infections/">Skin and Soft Tissue Infections</a></li>
<li><a href="/wiki/notes/Community-Acquired%20Pneumonia/">Community-Acquired Pneumonia</a></li>
<li><a href="/wiki/notes/Tick-Borne%20Diseases/">Tick-Borne Diseases</a></li>
<li><a href="/wiki/notes/Urinary%20Tract%20Infections/">Urinary Tract Infections</a></li>
<li><a href="/wiki/notes/Mycobacterium%20tuberculosis%20Infection/">Mycobacterium tuberculosis Infection</a></li>
<li><a href="/wiki/notes/Nontuberculous%20Mycobacterial%20Infections/">Nontuberculous Mycobacterial Infections</a></li>
<li><a href="/wiki/notes/Fungal%20Infections/">Fungal Infections</a></li>
<li><a href="/wiki/notes/Sexually%20Transmitted%20Infections/">Sexually Transmitted Infections</a></li>
<li><a href="/wiki/notes/Osteomyelitis%20MKSAP/">Osteomyelitis MKSAP</a></li>
<li>[[Fever of Unknown Ori</li>
</ul>

      </div>
    </div>
  </li>
  
  <li>
    <div class="">
      <a href="/wiki//notes/fulminant clostridium difficile/" class="peer">Fulminant Clostridium Difficile</a>
      <div
        role="none"
        class="absolute hidden px-8 py-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-ember prose-headings:hidden prose-hr:hidden"
      >
        <h1 id="fulminant-clostridium-difficile" tabindex="-1">fulminant clostridium difficile</h1>
<ul>
<li>related: <a href="/wiki/notes/clostridium%20difficile/">clostridium difficile</a></li>
</ul>
<!-- severe C. diff, fulminant c. diff definition, rx -->
<h2 id="definition" tabindex="-1">Definition</h2>
<p><img src="https://photos.thisispiggy.com/file/wikiFiles/20220731150653.png" alt=""></p>
<ul>
<li>IDSA define severe CDI by a <mark>leukocyte count ≥15,000/µL</mark> or a serum <mark>creatinine level &gt;1.5 mg/dL</mark>. The American College of Gastroenterology defines severe CDI by the <mark>presence of hypoalbuminemia</mark> (&lt;3 g/dL) plus <mark>leukocytosis</mark> (≥15,000/µL) or ==abdomin</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-6xl mx-auto mb-10 text-sm text-center mt-96">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
